Wednesday, May 26, 2020
Kolltan Pharmaceuticals, Inc.
Presentation followed by networking, refreshments & wine bar
is to develop novel therapeutics targeting proprietary discoveries in the
mechanisms of receptor tyrosine kinase (RTK) activation.
primary targets derive from discoveries made in the laboratory of Dr. Joseph
Schlessinger of Yale. The laboratory has characterized a novel molecular
mechanism underlying activation of RTKs, providing, for the first time, a clear
molecular explanation — at atomic resolution — for the oncogenic activity of
mutations that have been identified in a variety of human cancers. These
proprietary findings enable new strategies for selective inhibition of both
ligand-stimulated and oncogenic RTKs.
Kolltan plans to
target several RTKs playing well-validated roles in a range of cancers and other
diseases. The company will focus on the rapid translation of its intellectual
property into lead therapeutic molecules, and on the development of drugs that
complement and enhance existing standards of cancer therapy.
generation of cancer drugs, which act by interfering with the tyrosine kinase
activity of oncogenic tyrosine kinases, has been remarkably successful in the
treatment of a variety of cancers. Unfortunately, it is now clear that many
patients responding to these drugs develop resistance in later dosing cycles,
and ultimately fail therapy. Kolltan expects that the mechanism of action of its
drugs will be unaffected by such resistance.
Kolltan's strategy for its first
disease target is to focus initially on the development of a therapeutic human
monoclonal antobody, due to its anticipated shorter path to regulatory approval;
and later, on the possible discovery and development of synthetic small molecule
therapeutics, to which Kolltan's technology is equally applicable. Kolltan will
assess additional targets through proof of principle experiments.
The BioHaven Entrepreneurship Series features
presentations designed to showcase regionally developed life science
technologies that have progressed along the path to commercialization.
Speakers at the BioHaven events represent both the scientific and business side
of the enterprises.
The programs focus on key success factors of each company,
scientific or technological advantage, business model, and lessons learned in
starting and developing the business. The series also provides social networking
opportunities for scientists, researchers, and businessmen.
For a calendar of all the 2009-10 BioHaven events, click
|President & CEO, Kolltan Pharmaceuticals
Yaron Hadari, Ph.D.
Wednesday, May 26, 2020
3:30 P.M. Registration Open
4:00 P.M. Seminar
5:00 P.M. Networking, Refreshments & Wine Bar
The Anlyan Center auditorium, Yale Medical School.
Directions & Parking:
Registration is free, but please RSVP in advance. E-mail to email@example.com
or call the Yale OCR main number: 203-785-6209.
Lead sponsors: Wiggin and Dana and PricewaterhouseCoopers.
Also sponsored by Elm Street Ventures.
Presented by CURE and the Yale Office of Cooperative Research.